Surrozen secures FDA clearance for SZN‑8141 IND, unlocking $95.1 M private‑placement funding
Surrozen announced that the FDA has cleared its Investigational New Drug application for SZN‑8141, a bifunctional antibody targeting diabetic macular edema. The company plans to start dosing the first patient in the Phase 1b/2a DUET study in the fourth quarter of 2026. The clearance also satisfies a condition that will trigger the second tranche of its March 2025 private placement, expected to close around October 20, 2026. Proceeds will be used to fund the development of SZN‑8141, its sister candidate SZN‑8143, and general operating needs.
Why it matters
The funding milestone will provide roughly $95.1 million in gross proceeds, giving Surrozen cash to advance its ophthalmology pipeline and potentially reduce dilution risk for existing shareholders. The IND clearance moves the product into human testing, a key step that could affect the company’s valuation if early data are positive.
Key facts
- 1The FDA cleared Surrozen’s IND application for SZN‑8141, allowing the program to enter clinical development. globenewswire.com
- 2First patient dosing in the DUET Phase 1b/2a study is planned for Q4 2026. globenewswire.com
- 3The IND clearance satisfies a condition for the second closing of Surrozen’s March 2025 two‑tranche private placement. globenewswire.com
- 4The second closing is anticipated to occur on or about October 20, 2026. globenewswire.com
- 5The second closing is expected to generate approximately $95.1 million in gross proceeds before fees and expenses. globenewswire.com
- 6Initial data from the DUET study are projected for the second half of 2027. investing.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.